YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558)
Hong Kong
· Delayed Price · Currency is HKD 9.86
+0.50 (5.34%)
Apr 10, 2025, 4:08 PM HKT
HKG:1558 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 3,724 | 6,295 | 3,745 | 913.79 | 2,348 | Upgrade
|
| Revenue Growth (YoY) | -40.84% | 68.08% | 309.83% | -61.08% | -62.27% | Upgrade
|
| Cost of Revenue | 929.73 | 1,309 | 898.88 | 430.09 | 351.55 | Upgrade
|
| Gross Profit | 2,794 | 4,986 | 2,846 | 483.7 | 1,997 | Upgrade
|
| Selling, General & Admin | 1,539 | 1,933 | 1,555 | 880.07 | 1,472 | Upgrade
|
| Research & Development | 493.44 | 192.29 | 129.61 | 109.67 | 92.45 | Upgrade
|
| Other Operating Expenses | -26.25 | 63.83 | 842.69 | -51.11 | -397.14 | Upgrade
|
| Operating Expenses | 2,125 | 2,196 | 2,523 | 941.81 | 1,163 | Upgrade
|
| Operating Income | 668.96 | 2,790 | 322.72 | -458.11 | 833.69 | Upgrade
|
| Interest Expense | -97.53 | -227.4 | -281.65 | -243.81 | -244.21 | Upgrade
|
| Interest & Investment Income | 78.69 | 62.42 | 6.74 | 11.35 | 24.99 | Upgrade
|
| Earnings From Equity Investments | 0.29 | -0.03 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 4.79 | -16.86 | -241.43 | 49.2 | 150.14 | Upgrade
|
| EBT Excluding Unusual Items | 655.21 | 2,608 | -193.62 | -641.37 | 764.61 | Upgrade
|
| Impairment of Goodwill | - | - | -75.9 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.79 | 4.39 | 522.7 | 19.24 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 10.33 | -0.53 | -0.82 | -19.07 | -5.27 | Upgrade
|
| Asset Writedown | -86.52 | -485.39 | -212.94 | -25.98 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 251.09 | Upgrade
|
| Pretax Income | 577.23 | 2,127 | 39.42 | -667.18 | 1,010 | Upgrade
|
| Income Tax Expense | 94.52 | 270.95 | -9.82 | -79.46 | 173.02 | Upgrade
|
| Earnings From Continuing Operations | 482.71 | 1,856 | 49.24 | -587.72 | 837.41 | Upgrade
|
| Minority Interest in Earnings | - | 136.8 | 27.36 | 0.08 | 2.04 | Upgrade
|
| Net Income | 482.71 | 1,993 | 76.6 | -587.65 | 839.46 | Upgrade
|
| Net Income to Common | 482.71 | 1,993 | 76.6 | -587.65 | 839.46 | Upgrade
|
| Net Income Growth | -75.78% | 2501.24% | - | - | -56.25% | Upgrade
|
| Shares Outstanding (Basic) | 880 | 880 | 880 | 880 | 881 | Upgrade
|
| Shares Outstanding (Diluted) | 880 | 880 | 880 | 880 | 1,106 | Upgrade
|
| Shares Change (YoY) | - | - | - | -20.42% | 9.51% | Upgrade
|
| EPS (Basic) | 0.55 | 2.26 | 0.09 | -0.67 | 0.95 | Upgrade
|
| EPS (Diluted) | 0.55 | 2.26 | 0.09 | -0.67 | 0.53 | Upgrade
|
| EPS Growth | -75.73% | 2496.15% | - | - | -74.18% | Upgrade
|
| Free Cash Flow | - | 1,329 | 1,130 | -1,019 | 305.33 | Upgrade
|
| Free Cash Flow Per Share | - | 1.51 | 1.28 | -1.16 | 0.28 | Upgrade
|
| Dividend Per Share | - | - | - | - | 0.100 | Upgrade
|
| Dividend Growth | - | - | - | - | -84.61% | Upgrade
|
| Gross Margin | 75.03% | 79.21% | 76.00% | 52.93% | 85.03% | Upgrade
|
| Operating Margin | 17.96% | 44.33% | 8.62% | -50.13% | 35.50% | Upgrade
|
| Profit Margin | 12.96% | 31.66% | 2.05% | -64.31% | 35.75% | Upgrade
|
| Free Cash Flow Margin | - | 21.12% | 30.17% | -111.49% | 13.00% | Upgrade
|
| EBITDA | 1,051 | 3,172 | 691.48 | -206.55 | 950.24 | Upgrade
|
| EBITDA Margin | 28.23% | 50.40% | 18.46% | -22.60% | 40.47% | Upgrade
|
| D&A For EBITDA | 382.3 | 382.3 | 368.76 | 251.55 | 116.54 | Upgrade
|
| EBIT | 668.96 | 2,790 | 322.72 | -458.11 | 833.69 | Upgrade
|
| EBIT Margin | 17.96% | 44.33% | 8.62% | -50.13% | 35.50% | Upgrade
|
| Effective Tax Rate | 16.38% | 12.74% | - | - | 17.12% | Upgrade
|
Updated Sep 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.